Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?

  1. García Trevijano Cabetas, M.
  2. Escario-Gómez, M.
  3. González-Del Valle, L.
  4. Sobrino Jiménez, C.
  5. Bilbao Gomez-Martino, C.
  6. Romero-Garrido, J.A.
  7. Benedi-González, J.
  8. Espinosa Arranz, E.
  9. Díaz Almirón, M.
  10. Herrero Ambrosio, A.
Journal:
European Journal of Hospital Pharmacy

ISSN: 2047-9964 2047-9956

Year of publication: 2021

Volume: 30

Issue: 5

Pages: 268-272

Type: Article

DOI: 10.1136/EJHPHARM-2021-002798 GOOGLE SCHOLAR